Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age

Ballarini, T; Melo van Lent, D; Brunner, J; Schröder, A; Wolfsgruber, S; Altenstein, S; Brosseron, F; Buerger, K; Dechent, P; Dobisch, L; Ertl-Wagner, B; Fliessbach, K; Freiesleben, SD; Frommann, I; Glanz, W; Hauser, D; Haynes, JD; Heneka, MT; Janowitz, D; Kilimann, I; Laske, C; Maier, F; Metzger, CD; Munk, M; Perneczky, R; Peters, O; Priller, J; Ramirez, A; Rauchmann, B; Roy, N; Scheffler, K; Schneider, A; Spottke, A; Spruth, EJ; Teipel, SJ; Vukovich, R; Wiltfang, J; Jessen, F; Wagner, M

doi:10.1212/WNL.0000000000012067

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age

MPS-Authors

/persons/resource/persons84187

Scheffler, K
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

https://n.neurology.org/content/neurology/96/24/e2920.full.pdf
(Publisher version)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Ballarini, T., Melo van Lent, D., Brunner, J., Schröder, A., Wolfsgruber, S., Altenstein, S., et al. (2021). Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age. Neurology, 96(24), e2920-e2932. doi:10.1212/WNL.0000000000012067.

Cite as: https://hdl.handle.net/21.11116/0000-0009-F1DD-E

Abstract

Objective: To determine if following a Mediterranean-like diet (MeDi) relates to cognitive functions and in vivo biomarkers for Alzheimer's disease (AD), we analyzed cross-sectional data from the German Longitudinal Cognitive Impairment and Dementia Study METHOD: The sample (n=512, mean age: 69.5±5.9 years) included 169 cognitively normal participants and subjects at higher AD risk (53 AD relatives, 209 SCD and 81 MCI). We defined MeDi adherence based on the Food Frequency Questionnaire. Brain volume outcomes were generated via voxel-based morphometry on T1-MRI and cognitive performance with an extensive neuropsychological battery. AD-related biomarkers (Aβ42/40 ratio, pTau181) in cerebrospinal fluid were assessed in n=226 individuals. We analyzed the associations between MeDi and the outcomes with linear regression models controlling for several covariates. Additionally, we applied hypothesis-driven mediation and moderation analysis.
Results: Higher MeDi adherence related to larger mediotemporal gray matter volume (p<0.05 FWE corrected), better memory (β±SE = 0.03 ± 0.02; p=0.038), and less amyloid (Aβ42/40 ratio, β±SE = 0.003 ± 0.001; p=0.008) and pTau181 pathology (β±SE = -1.96±0.68; p=0.004). Mediotemporal volume mediated the association between MeDi and memory (40% indirect mediation). Finally, MeDi favorably moderated the associations between Aβ42/40 ratio, pTau181 and mediotemporal atrophy. Results were consistent correcting for ApoE-ε4 status.
Conclusion: Our findings corroborate the view of MeDi as a protective factor against memory decline and mediotemporal atrophy. Importantly, they suggest that these associations might be explained by a decrease of amyloidosis and tau-pathology. Longitudinal and dietary intervention studies should further examine this conjecture and its treatment implications.